资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Small Peptide Modulation of Fibroblast Growth Factor Receptor 3-Dependent Postnatal Lymphangiogenesis.

Lymphat Res Biol. 2019;

PerraultDavid P，LeeGene K，ParkSun Young，LeeSunju，ChoiDongwon，JungEunson，SeongYoung Jin，ParkEun Kyung，SungCynthia，YuRoy，BouzAntoun，PourmoussaAustin，KimSoo Jung，HongYoung-Kwon，WongAl

Products/Services Used	Details	Operation
Peptide Synthesis	… Sources or other reagents used are as follows: 9-cisRA (R4643; Sigma-Aldrich, Inc.) and FGF2 (Sigma). Peptide P3 (VSPPLTLGQLLS) and scrambled peptide (LQVLSTLPSLGP) were synthesized in vitro with guaranteed TFA removal and at a purity >98% (GenScript USA, Inc.) …	Get A Quote

摘要

The fibroblast growth factor receptor (FGFR) family includes transmembrane receptors involved in a wide range of developmental and postdevelopmental biologic processes as well as a wide range of human diseases. In particular， FGFR3 has been implicated in the mechanism by which 9-cis retinoic acid (9-cisRA) induces lymphangiogenesis and improves lymphedema. The purpose of this study was to validate the efficacy of a novel small peptide FGFR3 inhibitor， peptide P3 (VSPPLTLGQLLS)， and to elucidate the role of FGFR3 in 9-cisRA-induced lymphangiogenesis using this peptide.